What Acandis does

Acandis GmbH is a privately held German medical device company founded in 2006 and headquartered in Pforzheim, Germany, specialising in neurovascular implants for the endovascular treatment of stroke and adjacent cerebrovascular diseases. Its portfolio spans devices for haemorrhagic stroke (ACCERO, ACCLINO and DERIVO families of braided and laser-cut stents and flow diverters), ischaemic stroke (APERIO hybrid stent-retriever thrombectomy devices, CREDO stents, NeuroSpeed PTA balloon catheters, CARESTO carotid stents) and access/delivery (NeuroBridge and NeuroSlider microcatheters). The proprietary HEAL Technology — an antithrombogenic fibrin/heparin surface coating that mimics the final step of natural haemostasis — is applied across multiple device lines and is the company's primary technical differentiator, supported by a granted patent and ongoing post-market clinical studies (REVISAR, REheal, ICARUS, CARESTAR, RECHRUT, HYBRID, RESOLVE).

The company operates a hybrid commercial model: it sells directly via 12 wholly-owned subsidiaries in Germany, the United States, France, the United Kingdom, Austria, Switzerland, Turkey, Brazil, India, Vietnam, Poland and Colombia, and reaches 60+ additional countries through authorised distributor agreements. Revenue is generated primarily through one-time hardware sales of single-use implantable devices to hospitals and interventional neuroradiology departments, with procedure-volume-linked procurement contracts. Customers are tertiary-care and university hospitals performing mechanical thrombectomy, stent-assisted coiling, flow diversion, and ICAD interventions; physician training and clinical support are embedded in the commercial motion via hands-on workshops at the Pforzheim academy and at hospital sites globally.

Acandis is founder-managed under CEO Dr. Andreas Schüßler, who has led the company since inception, and in May 2026 received a minority growth-equity investment from Lauxera Capital Partners' €520 million Lauxera Growth II fund. The company has expanded its addressable market beyond acute stroke into pulsatile tinnitus (SiREX Stent, in RESOLVE pivotal study) and visceral/peripheral aneurysms (DERIVO peripher), and was recognised three times (2022, 2024, 2025) as a TOP 100 Innovator among German mittelstand companies. Revenue is not publicly disclosed; the company employs 101–250 people across its German operations and international subsidiaries.

Name

Acandis

Legal name

ACANDIS GmbH

Website

https://acandis.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

Acandis GmbH is a privately held German medical device company that designs, manufactures, and sells neurovascular implants — stents, flow diverters, thrombectomy devices, and microcatheters — for the endovascular treatment of stroke and adjacent cerebrovascular diseases, serving hospitals and interventional neuroradiologists in 60+ countries via 12 direct subsidiaries and a distributor network.

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Neurovascular medical devices
• Stroke treatment devices
• Flow diverter stents
• Mechanical thrombectomy devices
• Intracranial aneurysm treatment

Headquarters

HQ city

Pforzheim

HQ country

Germany

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Acandis develops, manufactures, and commercialises neurovascular medical devices for hospitals and interventional neuroradiology departments globally. Revenue is generated through direct sales via subsidiaries and through distributor networks, with medical devices sold as single-use implants typically quoted and procured on a contract or recurring hospital procurement basis.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Acandis develops, manufactures, and commercialises miniaturised implantable medical devices for the endovascular treatment of neurovascular diseases, including braided and laser-cut stents, flow diverters, mechanical thrombectomy devices, PTA balloon catheters, and microcatheters for stroke treatment. The company sells single-use implants to hospitals and interventional neuroradiology departments through a global network of direct subsidiaries and distributors across 60+ countries.

Product overview

Acandis is a German medical technology company specializing in neurovascular devices for stroke treatment. The product portfolio consists of three main categories: (1) Devices for Hemorrhagic Stroke including ACCERO® stents (braided, visible), ACCLINO® laser-cut stents, and DERIVO® flow diverters (braided self-expanding); (2) Devices for Ischemic Stroke including APERIO® hybrid thrombectomy devices, CREDO® stents for intracranial stenosis, NeuroSpeed® PTA balloon catheters, and CARESTO® carotid stents; (3) Access and Delivery products including NeuroBridge® catheters and NeuroSlider® microcatheters (including DLC variants). Many products are available with HEAL Technology coating for improved healing. The company also offers the SiREX® Stent for venous sinus stenosis treatment. Products are complemented by training programs, sizing support services, and clinical studies.

Differentiator

Problem solved

Functional benefit

Brands

• HEAL Technology: Proprietary antithrombogenic coating technology for stents and flow diverters that mimics natural hemostasis

Products and services

• DERIVO 2 Embolisation Device Self-expanding braided flow diverter implant for the endovascular treatment of intracranial aneurysms through flow diversion, redirecting blood flow away from the aneurysm while maintaining patency of side branches. Designed for interventional neuroradiologists treating unruptured and ruptured aneurysms.
• DERIVO 2heal Embolisation Device HEAL Technology-coated version of the DERIVO 2 flow diverter, with antithrombogenic fibrin/heparin surface that reduces thrombogenicity and supports faster endothelialisation in intracranial aneurysm treatment.
• DERIVO Embolisation Device Original-generation braided, self-expanding flow diverter for intracranial aneurysm treatment, featuring high flexibility for atraumatic wall apposition.
• DERIVO mini Embolisation Device Smaller-profile braided flow diverter designed for treatment of distal intracranial aneurysms, compatible with small delivery systems.
• DERIVO peripher Embolisation Device Braided, self-expanding flow diverter for peripheral and visceral artery aneurysm treatment, featuring nitinol composite wires with platinum core and compatibility with 0.027–0.039 inch delivery systems. Not available in the United States.
• ACCERO Stent Braided microstent with platinum-nitinol composite wire technology for stent-assisted coiling of wide-necked intracranial aneurysms, providing full radiopacity and flexibility.
• ACCERO heal Stent HEAL Technology-coated version of the ACCERO braided microstent, with antithrombogenic surface for stent-assisted coiling of intracranial aneurysms.
• ACCERO Rex Stent Specialised variant of the ACCERO braided stent designed specifically for treatment of giant cerebral aneurysms via stent-assisted coiling.
• ACCLINO flex plus Stent Low-profile laser-cut stent for treatment of wide-neck intracranial aneurysms with enhanced flexibility and improved deliverability.
• ACCLINO heal Stent HEAL Technology-coated version of the ACCLINO laser-cut stent for wide-neck intracranial aneurysm treatment, with antithrombogenic surface.
• APERIO Hybrid Thrombectomy Device Hybrid-cell design stent retriever for mechanical thrombectomy in acute ischemic stroke, combining open and closed cell design elements for effective clot engagement, visibility and trackability.
• APERIO Hybrid17|21 Thrombectomy Device Next-generation hybrid thrombectomy stent retriever available in 1.7mm and 2.1mm sizes for treatment of distal and proximal vessel occlusions in acute ischemic stroke.
• CREDO Stent Self-expandable microstent for the treatment of intracranial atherosclerotic disease (ICAD) and acute indications, including rescue stenting.
• CREDO heal Stent HEAL Technology-coated version of the CREDO self-expandable microstent for intracranial stenosis and rescue stenting, with improved endothelialisation.
• NeuroSpeed PTA Balloon Catheter Percutaneous transluminal angioplasty (PTA) balloon catheter for pre-dilation and treatment of intracranial arterial stenosis, used in combination with CREDO stents as part of Acandis' integrated ICAD Treatment System.
• CARESTO heal Stent Third-generation carotid artery stent with HEAL antithrombogenic coating for the treatment of carotid artery disease, featuring high flexibility and full visibility.
• NeuroBridge Catheter Intermediate catheter for neurovascular access and support during interventional procedures, used to facilitate delivery of therapeutic devices.
• NeuroSlider Microcatheter Microcatheter for device delivery in neurovascular interventions, used as a delivery conduit for therapeutic devices such as stents and flow diverters.
• NeuroSlider DLC (Micro)Catheter Dual-layer composite (DLC) microcatheter with enhanced trackability and support for delivery of flow diverters and other devices in neurovascular interventions. First Acandis product to receive CE certification under EU MDR (2023).
• SiREX Stent Braided, fully radiopaque implant specifically designed for the treatment of disabling pulsatile tinnitus caused by lateral venous sinus stenosis. Currently under clinical investigation in the international RESOLVE study (78 patients across five European centres).
• ICAD Treatment System Integrated treatment system combining the CREDO heal self-expanding microstent with the NeuroSpeed PTA balloon catheter for comprehensive intracranial atherosclerotic disease (ICAD) treatment in a single-pass endovascular therapy approach.

Quantifiable outcome

• REVISAR study: Publication of clinical and angiographic outcomes for APERIO thrombectomy device in distal vessel occlusions (2025)
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Hôpital Lariboisière PariscoreStrategic or Co-development PartnerCoordinating Principal Investigator site for the RESOLVE clinical study (SiREX Stent for pulsatile tinnitus). Prof. Emmanuel Houdart serves as Coordinating PI, with Dr. Alexis Guédon and Dr. Francesco Arpaia as clinical team members. The hospital is leading the international pivotal trial across five European centres with 78 patients.
• Universitätsklinikum Hamburg-Eppendorf (UKE)coreStrategic or Co-development PartnerKey opinion leader site for multiple Acandis clinical studies. PD Dr. Maxim Bester is PI for the ACCERO (heal) PMCF registry (154 patients, NCT03957382) and the REheal study. UKE also hosts regular Acandis training workshops (DERIVO, ICA aneurysm training).
• Städtisches Klinikum SolingencoreStrategic or Co-development PartnerKey clinical study site and training partner. PD Dr. Hannes Nordmeyer serves as coordinating PI for the CARESTAR study (536 patients, NCT07166731) and PI for the RECHRUT study (153 patients). The hospital hosts regular CREDO workshop training sessions.
• Universitätsspital BaselcoreStrategic or Co-development PartnerLead site for the ICARUS investigator-initiated study (498 patients) evaluating CREDO heal Stent and NeuroSpeed PTA Balloon Catheter for ICAD-related stroke, directed by Prof. Dr. Marios Psychogios. Acandis is listed as a collaborator.
• Universitätsklinikum BonncoreStrategic or Co-development PartnerPrincipal investigator site for the REVISAR PMCF study (130 patients, completed, results published 2025) evaluating APERIO thrombectomy devices. Prof. Dr. Franziska Dorn is the PI.
• Universitätsklinikum MagdeburgcoreStrategic or Co-development PartnerPrincipal investigator site for the REheal PMCF study (352 patients, NCT05543447) evaluating the DERIVO 2heal Embolisation Device. Prof. Dr. Daniel Behme is the PI.
• LINNC ParisminorGTM or Marketing PartnerAcandis participates in the annual LINNC Paris conference (1–3 June 2026), a major neurointervention educational event, as an exhibitor and presenter of clinical data.
• ESMINT (European Society of Minimally Invasive Neurological Therapy)minorGTM or Marketing PartnerAcandis has participated as an exhibitor at ESMINT annual congresses (2024 Marseille, 2025 Marseille, 2026 Marseille) and hosts an annual Distributor Meeting alongside ESMINT.
• SOBRICE (Sociedade Brasileira de Radiologia Intervencionista e Cirurgia Endovascular)minorGTM or Marketing PartnerAcandis has participated at SOBRICE annual meetings (2021, 2022, 2024) in São Paulo, Brazil, supporting its Latin American distributor and subsidiary presence.

Scale indicators6 records

Recent moves13 records

Expansion highlights7 records

Broad incumbents

• Stryker (Neurovascular): Stryker's Neurovascular division (formed via the acquisition of Cerenovus-related assets and others) is a global leader in hemorrhagic and ischemic stroke devices, including flow diverters (Surpass), stent retrievers (Trevo), and detachable coils. Directly competes with Acandis' DERIVO flow diverters and APERIO thrombectomy devices across hospitals globally.
• Cerenovus (Johnson & Johnson MedTech): Cerenovus is J&J's neurovascular franchise offering a comprehensive portfolio of coils, flow diverters, stent retrievers, and access devices. Direct overlap with Acandis across both hemorrhagic (coils/flow diversion) and ischemic stroke (stent retrievers) categories.
• Medtronic Neurovascular: Medtronic's Neurovascular business (inheriting Covidien/Stryker-era assets) competes across the full stroke spectrum including Pipeline flow diverters and Solitaire stent retrievers. As one of the largest medical device companies globally, Medtronic's scale, hospital contracts, and R&D resources make it Acandis' most formidable direct competitor.

Emerging players

• InspireMD: InspireMD develops neurovascular and carotid stents with mesh protection technology (CGuard). Comparable to Acandis' CARESTO carotid stent franchise and DERIVO flow diverter technology, serving overlapping customer base.
• MIVI Neuroscience: MIVI Neuroscience develops stroke treatment devices including the Q Aspiration catheter and Revive SE stent retriever. Direct competitor to Acandis' APERIO thrombectomy line, with overlapping target customers in stroke centers.

Direct peers

• Wallaby Medical (Phenox): Wallaby Medical (acquired by Phenox) develops the Avenir coil system and other neurovascular devices. Direct peer to Acandis in the aneurysm treatment category with overlapping geographic coverage and target customers.
• Penumbra: Penumbra is a U.S.-listed neurovascular company specializing in mechanical thrombectomy (aspiration-based, e.g., RED, Jet), stroke catheters, and more recently embolization devices. Direct competitor to Acandis' APERIO stent-retriever thrombectomy franchise and increasingly in flow diversion, with a strong U.S. commercial footprint.
• Rapid Medical: Rapid Medical is an Israel-based neurovascular company developing adjustable stent retrievers (Tigertriever) and flow diverters (Comaneci). Direct peer with comparable focus on ischemic and hemorrhagic stroke, recently acquired by MicroPort further escalating competitive intensity.
• Phenox GmbH: Phenox is a German neurovascular device company offering pCONUS stents, p64 flow diverters, and pRESET stent retrievers. A direct peer with similar product portfolio, German origin, and target customer base (interventional neuroradiologists) competing head-to-head with Acandis in Europe.
• MicroPort NeuroTech: MicroPort NeuroTech (part of Shanghai MicroPort Medical) develops and markets the Tubridge flow diverter and other neurovascular devices. Directly comparable to Acandis in flow diversion technology with competing global commercial reach, particularly in China and Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCwFS44lSJoFYwU2dO_0TrBw
• LinkedInde.linkedin.com/company/acandis-gmbh-&-co-kg
• Xx.com/Acandisgmbh
• Facebookfacebook.com/AcandisGmbH

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries11 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acandis